Exelixis, Inc. Announces Fourth Quarter And Full Year 2013 Financial Results
Published: Feb 21, 2014
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Q4 2013 Highlights and Recent Events
•Completed enrollment in COMET-1, the phase 3 study of cabozantinib versus prednisone with the primary endpoint of overall survival in patients with advanced metastatic castration-resistant prostate cancer (CRPC).
Help employers find you! Check out all the jobs and post your resume.